Can I continue to take Axitinib if I am resistant to it?

Once a patient develops resistance to axitinib (Axitinib), the effectiveness of continued use of the drug is often limited. Drug resistance means that the tumor is less sensitive to the drug and the drug is unable to effectively inhibit or control the growth of the tumor. In this case, doctors will often consider adjusting the treatment plan rather than continuing to use the drug that has lost its effectiveness.

Possible processing strategies include:

1.Switching treatment drugs: When a patient becomes resistant to axitinib, doctors may consider switching to other targeted therapies or immunotherapy drugs. Selection of new treatment options is often based on the patient's pathology, overall health, and possible resistance mechanisms.

2.Combination therapy: Sometimes doctors will consider a combination therapy strategy, in which axitinib is combined with other drugs. This strategy aims to act on tumors simultaneously through multiple mechanisms to improve the comprehensiveness of treatment.

3.Participation in clinical trials: For some patients, participation in a clinical trial may be an option, especially if new treatments or strategies are being sought. Clinical trials provide the opportunity to try the latest treatments.

Axitinib has been launched in China and has been included in medical insurance. Patients can purchase it domestically. The price of 5mg*28 tablets is about 5,000 to 6,000 yuan. For specific prices, please consult the local hospital pharmacy. There are original and generic axitinib drugs abroad. The original drug is Pfizer's original drug, and the price is about 6,000 yuan; the generic drugs are mainly Bangladeshi generics and Indian generics. The price of Bangladeshi generics in 5mg*60 tablets is more than 1,000 yuan, and the price of Indian generics is around a few hundred yuan. The ingredients of original drugs and generic drugs are basically the same.